Taurine Fights Gut Inflammation by Clearing Toxic Mitochondrial RNA

Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, is managed with anti-TNF biologics, but a significant portion of patients either do not respond or eventually lose response. This study identifies a novel immunometabolic circuit involving taurine, a sulfur-containing amino acid abundant in intestinal tissue, and opens potential new avenues for IBD treatment.

The research team analyzed intestinal biopsy tissue from IBD patients and found that taurine levels were significantly elevated compared to healthy controls, but inversely correlated with disease severity—suggesting taurine functions as a protective, disease-modulating metabolite rather than simply a marker of inflammation. Using cell and animal models, the investigators demonstrated that TNF directly induces taurine biosynthesis within intestinal epithelial cells, establishing a feedback mechanism in which the primary inflammatory driver also triggers a counter-regulatory response.

A pivotal discovery was that taurine increases the production of angiogenin, an endoribonuclease best known for its role in angiogenesis but here identified as a key regulator of innate immunity. Angiogenin selectively degrades mitochondrial RNA (mtRNA) that leaks from damaged mitochondria. Released mtRNA acts as a damage-associated molecular pattern (DAMP), activating macrophage inflammatory programs. By boosting angiogenin-mediated mtRNA clearance, taurine effectively reduces this DAMP signaling and suppresses macrophage-driven intestinal inflammation.

The mechanistic chain—TNF → intestinal epithelial taurine synthesis → angiogenin upregulation → mtRNA degradation → reduced macrophage activation—represents a previously unrecognized innate immune regulatory axis. Crucially, this pathway is partially self-limiting: as inflammation drives TNF, TNF drives taurine production, which in turn restrains excessive inflammation. When this circuit is insufficient (as suggested by the inverse correlation between taurine and disease severity), disease progresses.

These findings carry significant translational potential. Taurine supplementation or strategies that enhance angiogenin activity could serve as adjuncts to anti-TNF therapy, potentially rescuing non-responders or reducing the dose of biologics needed. Because taurine is a safe, naturally occurring compound already available as a dietary supplement, the path to clinical investigation may be relatively straightforward. The study also broadens understanding of how metabolites mediate cross-talk between the epithelium and immune cells in chronic inflammatory disease.